Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart JA, Bear HD, Glass AG, Bornstein R, et al. Mamounas EP, et al. Among authors: hamm jt. Am J Clin Oncol. 1994 Oct;17(5):374-81; discussion 382. doi: 10.1097/00000421-199410000-00002. Am J Clin Oncol. 1994. PMID: 7522393 Clinical Trial.
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N. Fisher B, et al. Among authors: hamm jt. J Clin Oncol. 1999 Nov;17(11):3374-88. doi: 10.1200/JCO.1999.17.11.3374. J Clin Oncol. 1999. PMID: 10550131 Clinical Trial.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Geyer CE Jr, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N. Geyer CE Jr, et al. Among authors: hamm jt. Breast Cancer Res Treat. 2022 Jun;193(3):555-564. doi: 10.1007/s10549-021-06417-y. Epub 2022 Mar 1. Breast Cancer Res Treat. 2022. PMID: 35230585 Free PMC article.
Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer.
Blumenreich MS, Sheth SP, Miller CL, Farnsley ES, Kellihan MJ, Joseph UG, Hamm JT, Seeger J, Robinson LH, Hagan PC, et al. Blumenreich MS, et al. Among authors: hamm jt. Am J Clin Oncol. 1994 Apr;17(2):163-5. doi: 10.1097/00000421-199404000-00015. Am J Clin Oncol. 1994. PMID: 8141109 Clinical Trial.
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Moore MJ, et al. J Clin Oncol. 2007 May 20;25(15):1960-6. doi: 10.1200/JCO.2006.07.9525. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452677 Clinical Trial.
72 results